Natalizumab is effective in controlling the inflammatory rebound after its discontinuation and failure of an alternative treatment
| Autor: | Marie Miquel, Elsa Krim, Raluca Marasescu, Bruno Barroso, Stéphanie Demasles, Mikael Bonnan |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Adult
Male Oncology medicine.medical_specialty viruses JC virus Antibodies Viral medicine.disease_cause Multiple Sclerosis Relapsing-Remitting Natalizumab Internal medicine medicine Humans Immunologic Factors Risk factor Seroconversion business.industry Multiple sclerosis Progressive multifocal leukoencephalopathy General Medicine medicine.disease JC Virus Discontinuation Neurology Retreatment Immunology Neurology (clinical) Complication business medicine.drug |
| Zdroj: | Multiple Sclerosis and Related Disorders. 4:380-382 |
| ISSN: | 2211-0348 |
| DOI: | 10.1016/j.msard.2015.04.005 |
| Popis: | Progressive multifocal leukoencephalopathy (PML) is the most feared complication when natalizumab (NAT) is used in the treatment of relapsing multiple sclerosis (MS). JC virus serologic status is a currently established risk factor for PML. When seroconversion occurs, NAT discontinuation should be based on a solid rationale to avoid an MS inflammatory resurgence. The JC virus index value may also provide further useful information to help practitioners and patients in their decision process. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect